Abstract
Five of 43 patients (11.6%) with ductal carcinoma in situ of the breast presented with p53 autoantibodies at diagnosis. Three seropositive patients demonstrated tumour sizes of ≤ 5 mm. There was no association of p53 autoantibody status with age, clinical presentation, histological subtype, tumour size, grading, p53 immunohistochemistry or hormone receptor status.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Angelopoulou, K, Diamandis, EP, Sutherland, DJ, Kellen, JA & Bunting, PS (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58: 480–487
Angelopoulou, K, Stratis, M & Diamandis, EP (1997) Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 70: 46–51
Coles, C, Condie, A, Chetty, U, Steel, CM, Evans, HJ & Prosser, J (1992) p53 mutations in breast cancer. Cancer Res 52: 5291–5298
Crawford, LV, Pim, DC & Bulbrook, RD (1982) Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403–408
Davidoff, AM, Iglehart, JD & Marks, JR (1992) Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89: 3439–3442
Holland, R & Hendriks, JH (1994) Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation. Semin Diagn Pathol 11: 181–192
Lagios, MD (1990) Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am 70: 853–871
Maass, JD, Gottschlich, S, Lippert, BM, Niemann, AM, Gorogh, T & Werner, JA (1996) Antibody formation to cellular p53 protein in patients with squamous cell carcinomas of the upper respiratory and digestive system. Laryngorhinootologie 75: 53–56
Mudenda, B, Green, JA, Green, B, Jenkins, JR, Robertson, L, Tarunina, M & Leinster, SJ (1994) The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 69: 1115–1119
Peeters, PH, Verbeek, AL, Hendriks, JH & van Bon, MJ (1989) Screening for breast cancer in Nijmegen. Report of 6 screening rounds, 1975–1986. Int J Cancer 43: 226–230
Peyrat, JP, Bonneterre, J, Lubin, R, Vanlemmens, L, Fournier, J & Soussi, T (1995) Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 345: 621–622
Remmele, W & Stegner, HE (1987) [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8: 138–140
Runnebaum, IB, Nagarajan, M, Bowman, M, Soto, D & Sukumar, S (1991) Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 88: 10657–10661
Schlichtholz, B, Legros, Y, Gillet, D, Gaillard, C, Marty, M, Lane, D, Calvo, F & Soussi, T (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380–6384
Schnitt, SJ, Silen, W, Sadowsky, NL, Connolly, JL & Harris, JR (1988) Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med 318: 898–903
Silverstein, MJ (1997). Ductal Carcinoma In Situ of the Breast. Williams and Wilkins: Baltimore
Sjogren, S, Inganas, M, Norberg, T, Lindgren, A, Nordgren, H, Holmberg, L & Bergh, J (1996) The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173–182
Winter, SF, Minna, JD, Johnson, BE, Takahashi, T, Gazdar, AF & Carbone, DP (1992) Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168–4174
Author information
Authors and Affiliations
Additional information
Correspondence to:IB Runnebaum
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Regele, S., Kohlberger, P., Vogl, F. et al. Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast. Br J Cancer 81, 702–704 (1999). https://doi.org/10.1038/sj.bjc.6690751
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690751
Keywords
This article is cited by
-
Can serum autoantibodies be a potential early detection biomarker for breast cancer in women? A diagnostic test accuracy review and meta-analysis
Systematic Reviews (2022)
-
Early Detection of Breast Cancer
Molecular Diagnosis & Therapy (2009)